All Clinical Trials articles – Page 2
-
NewsCovid-19 is forcing pharma to rethink clinical trials
Drug trials have become a casualty of Covid-19, but the pandemic is also prompting change
-
Opinion
Hopes and fears for remdesivir
Available resources for testing coronavirus treatments need to be used wisely
-
Opinion
Does the drug work, or not?
Coronavirus trials reveal the murky reality of disentangling compounds’ effects on human biology
-
-
Opinion
Vaccine development against the clock
How long will it take to develop a coronavirus vaccine and why is it so hard?
-
Business
Can existing drugs slow Covid-19?
The fastest route to treatments may be to repurpose existing drugs – if they work
-
-
Business
Sixth in a line of Alzheimer’s drugs fails in trials
Treatments designed to stop amyloid peptide formation all seem to cause cognitive impairment rather than prevent it
-
Opinion
Are new drugs better than existing ones?
Should companies be made to change the way they run clinical trials?
-
Business
Cleaning up clinical trials
Campaigns to enforce complete and correct reporting of trial data are beginning to take hold
-
News
Tracker to name and shame for failure to report clinical trial results
Developers of online tool hope that it will improve accountability
-
Business
Call for overhaul of EU rules on GMO clinical trial
Rules designed around genetically modified plants crops are holding back new cell and gene-based medicines
-
Feature
The long road to an HIV vaccine
A vaccine may not be available anytime soon, but its proponents are hard at work
-
Business
AstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
Research
Lilly pushes continuous drug production limits
Integrated flow synthesis and purification process for prexasertib meets high industry standards
-
Opinion
Unpicking a clinical trial death
A new study shows up off-target effects of a drug that proved deadly, and highlights the pitfalls of drug discovery
-
Opinion
How safe should drugs be?
What does spotting new risks in approved medicines say about how effective regulators are?
-
Research
Catalyst puts chiral twist on phosphorus drugs
Simple molecule overcomes headache of phosphorus stereochemistry in antiviral drug synthesis
-
News
Fears that gene-editing cancer trials are premature
Warnings from geneticists that Crispr trial failures could knock promising technique’s prospects
-
Opinion
Regulatory tightropes
When lobbying and marketing clash with scientific evidence, regulators walk a fine line
